US Patent

US10077271 — Methods and compositions for inhibiting the interaction of menin with MLL proteins

Composition of Matter · Assigned to University of Michigan System · Expires 2036-03-16 · 10y remaining

Vulnerability score 0/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects methods and compositions for inhibiting the interaction of menin with certain proteins, useful for treating various diseases.

USPTO Abstract

The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.

Drugs covered by this patent

Patent Metadata

Patent number
US10077271
Jurisdiction
US
Classification
Composition of Matter
Expires
2036-03-16
Drug substance claim
Yes
Drug product claim
Yes
Assignee
University of Michigan System
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.